SCHEMBL9889667

SCHEMBL9889667

Cc1cc(Oc2ccc(CCOc3nc(=O)c(Cc4c(F)cc(F)cc4F)c[nH]3)cc2)ccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 1/20 0.42
GPR84 Q9NQS5 1/20 0.35
PPARA Q07869 5/20 0.34
PPARG P37231 4/20 0.34
KCNH2 Q12809 2/20 0.33
P2RX7 Q99572 2/20 0.32
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
PPARD Q03181 2/20 0.31
PARP1 P09874 1/20 0.31
PARP3 Q9Y6F1 1/20 0.31
MMP10 P09238 1/20 0.31
MMP8 P22894 1/20 0.31
MMP13 P45452 1/20 0.31
HTR2A P28223 1/20 0.31
SLC6A4 P31645 1/20 0.31
P2RX3 P56373 1/20 0.30
MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9104844 0.88 PLA2G7 (0.57) PLA2G7GPR84
SCHEMBL9107934 0.86 PLA2G7 (0.42) PLA2G7GPR84PPARAPPARGKCNH2
SCHEMBL9104009 0.84 PLA2G7 (0.56) PLA2G7GPR84PPARAPPARGKCNH2
SCHEMBL9889666 0.83 PLA2G7 (0.51) PLA2G7GPR84PPARAPPARG
SCHEMBL9104046 0.83 PLA2G7 (0.53) PLA2G7GPR84
SCHEMBL9234987 0.83 PLA2G7 (0.44) PLA2G7GPR84PPARAPPARGP2RX3
SCHEMBL9106542 0.81 PLA2G7 (0.41) PLA2G7GPR84PPARGCYP3A4
SCHEMBL9889690 0.81 PPARG (0.37) PLA2G7GPR84PPARGKCNH2P2RX7
SCHEMBL9889665 0.80 PLA2G7 (0.39) PLA2G7GPR84PPARG
SCHEMBL9889689 0.78 PLA2G7 (0.38) PLA2G7GPR84PPARGKCNH2P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174968-B2 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 GLAXO GROUP LIMITED (GB) 2015-11-03 US disclosed
US-20150099756-A1 PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 GLAXO GROUP LIMITED (GB) 2015-04-09 US disclosed
US-8637536-B2 Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-01-28 US disclosed
US-20130252963-A1 PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20120142717-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142717-A1 COMPOUNDS LIPG, PLA2G1B, ENPP2 PLA2G7 6/4885GPR84 742/4885PPARA 484/4885
US-20130252963-A1 PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 PLA2G1B, PLA2G4A, PLA2G4B PLA2G7 4/4885GPR84 446/4885PPARA 293/4885
US-20150099756-A1 PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 PLA2G1B, PLA2G4A, PLA2G4B PLA2G7 4/4885GPR84 403/4885PPARA 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.